4,901 trials
Healthy Volunteers
Primary: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-831 — 714.8; 597.5; 4563; 4665…
Healthy Volunteers
Primary: Change in Non-displaceable Binding Potential (BP-ND) in the TAK-041+AMPH Condition Compared to AMPH Alone — 17; 36; 14; 23 percentage of reduction
Neoplasms · Prostate Cancer · Lung Cancer
Primary: Number of Participants With Serious and Non-serious Adverse Events — 6; 4 Participants
Healthy Volunteers
Primary: Maximum Drug Concentration of Metformin in Plasma After Single Dose Administration (Cmax) — 1550; 1460 microgram per liter (mcg/L)
Gram-Positive Bacterial Infections
Primary: Maximum Observed Drug Concentration in Plasma (Cmax) of Tedizolid Phosphate (Prodrug) — 76.3; 82.4; 710; 234 ng/mL
Fungal Infection
Primary: Steady State (ss) Average Concentration (Cavg) of Posaconazole of Serial PK (Subgroup 1) on Day 10 — 2986.28 ng/mL
Helminthic Infection
Primary: Number of Subjects Reporting Adverse Events (AEs) Related to Oxfendazole for Arms 1, 2, and 3 — 3; 3; 1 Participants
Healthy Volunteer
Primary: Metabolic Profile: Percentage of Free Thiophenol M1 in the Blood Plasma — 37.5 Percentage of Free Thiophenol M1
Colorectal Carcinoma
Primary: Pharmacological Effect on Cyclic Guanosine Monophosphate (cGMP) Levels for Dolcanatide Arm Versus (vs.) Placebo, as Measured by the Differences in Mean cGMP Levels After…
Infections, Bacterial
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero (Pre-dose) Extrapolated to Infinity (AUC[0-inf]) for Plasma Gepotidacin — 15894.7; 19505.7; 25415.5…
Healthy Volunteer
Primary: Plasma Concentration of Dalcetrapib Active Form — 285; 272; 294; 231 ng/mL
Solid Tumor
Primary: Time-matched Mean Change From Baseline in Corrected QT Intervals Based on the Fridericia's Correction Fomulation (QTcF) — 3.9; 3.5; 1.6; -0.3 millisecond (msec)
HIV
Primary: Number of Grade 2 or Higher Related Adverse Events — 11 Events
Celiac Disease
Primary: Number of Participants for Which Treatment Was Concluded to be Safe — 6; 18; 4; 5 participants
Cancer, Solid Tumor
Primary: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0…